HYEX · XBRL financial data

Healthy Extracts financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (HYEX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	1,277	1,677	2,251	2,486	3,113	4,512
Cost of revenue	1,855	771	880	864	1,202	2,090
Cost of goods and services sold	465	346	783	864	1,202	2,090
Gross profit	(578)	695	1,372	1,622	1,911	2,422
General and administrative	1,475	2,584	2,283	3,866	2,094	3,366
Total operating expenses	3,055	2,584	2,283	3,866	2,094	3,366
Other income (expense)	—	(98)	(72)	(229)	(658)	63
Income tax expense (benefit)	—	—	0	0	0	0
Net income (loss)	(2,576)	(1,987)	(983)	(2,473)	(841)	(881)

† Share count changed about 1/116 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (HYEX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	59	222	66	19	112	147
Accounts receivable	13	133	106	30	11	188
Inventory	2,418	1,958	1,819	1,626	1,361	843
Total current assets	2,490	2,313	1,991	1,900	1,659	1,327
Right-of-use asset	—	—	0	72	9	0
Goodwill	193	193	193	193	193	21,124
Total assets	3,115	3,030	2,781	2,635	2,378	27,825
Accounts payable	65	37	91	117	52	108
Accrued liabilities	9	59	95	215	249	614
Total current liabilities	262	559	903	1,680	1,968	1,688
Lease liability, non-current	—	—	0	9	0	344
Total liabilities	262	—	—	—	1,968	3,795
Accumulated deficit	(12,956)	(14,944)	(15,927)	(18,400)	(19,240)	(20,121)
Total stockholders' equity	2,854	2,471	1,878	955	410	24,030
Total liabilities and equity	3,115	3,030	2,781	2,635	2,378	27,825
Common shares outstanding (cover page) thousands of shares	308,887	338,092	345,172	2,964	2,989	16,891

† Share count changed about 1/116 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (HYEX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(2,576)	(1,987)	(983)	(2,473)	(841)	(881)
Stock-based compensation	—	0	0	—	—	—
Depreciation and amortization	9	5	—	—	—	—
Net cash from operating activities	1,903	(901)	(335)	(416)	282	166
Purchases of property and equipment	—	0	8	0	—	—
Net cash from investing activities	(116)	(96)	(8)	0	0	56
Proceeds from issuing common stock	4,406	995	(11)	(90)	0	—
Net cash from financing activities	1,944	1,160	187	370	(189)	(187)
Net change in cash	(74)	163	(156)	(46)	93	35

† Share count changed about 1/116 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Healthy Extracts	190	2,067	306*	14.7M	—	Q2 FY26 10-QJun 30, 2026
Theriva Biologics	11,337	0*	(3,085)*	45.9M	3.7 quarters	Q2 FY26 10-QJun 30, 2026
China Pharma Holdings	305	948	(33)*	43.0M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Jaguar Health	3,788	1,225	(5,338)*	not reported	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Synlogic	13,183	0	(922)*	12.2M	14.3 quarters	Q2 FY26 10-QJun 30, 2026
Matinas BioPharma Holdings	761	not reported	(1,836)*	14.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Soligenix	9,811	not reported	(1,707)*	21.8M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Q/C Technologies	308	not reported	(1,819)*	8.2M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Polomar Health Services	179	1,529	121*	28.4M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.